Reported 2 days ago
Insmed Inc. (NASDAQ:INSM) saw its stock rise 7.75% to $97.98 following its announcement of a $650 million fundraising plan aimed at advancing its drug candidates and expanding business operations. The fundraising comes after positive results from a phase 2 trial for its pulmonary arterial hypertension treatment, TPIP. Major investment firms have issued 'buy' recommendations for the stock, projecting a target price between $102 and $110.
Source: YAHOO